MannKind Receives FDA Approval for Afrezza Label Update

MannKind has announced that the FDA has approved an update to the Prescribing Information for Afrezza Inhalation Powder. The updated labeling revises recommendations for starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. The change is based on modeling data and in vivo results from two clinical trials. The update aims to provide clearer guidance for healthcare providers transitioning patients to inhaled insulin.